Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

NCT07701161 is registered in ClinicalTrials.gov with Neurogen Biomarking LLC as lead sponsor.

NCT NCT07701161
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07701161 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
Lead sponsor
Neurogen Biomarking LLC
Phase
Observational
Overall status
Recruiting
Start date
January 13, 2025
Completion date
August 1, 2026
Enrollment
1,000 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer s disease, biomarkers, mci conversion to dementia, ptau217